An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype

Key Inclusion Criteria: * APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2 * Chronic kidney disease with persistent albuminuria Key Exclusion Criteria: * Organ or bone marrow transplantation * History of active cancer within past 2 years, except for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer * Conditions that may alter drug absorption, e.g., history of bariatric surgery * Type I diabetes * Pregnant or currently nursing Other inclusion/exclusion criteria defined in protocol apply.